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ABSTRACT
Tumor microenvironment coevolves with and simultaneously sustains cancer 
progression. In prostate carcinoma (PCa), cancer associated fibroblasts (CAF) have 
been shown to fuel tumor development and metastasis by mutually interacting with 
tumor cells. Molecular mechanisms leading to activation of CAFs from tissue-resident 
fibroblasts, circulating bone marrow-derived fibroblast progenitors or mesenchymal 
stem cells are largely unknown. Through integrated gene and microRNA expression 
profiling, we showed that PCa-derived CAF transcriptome strictly resembles that of 
normal fibroblasts stimulated in vitro with interleukin-6 (IL6), thus proving evidence, 
for the first time, that the cytokine is able per se to induce most of the transcriptional 
changes characteristic of patient-derived CAFs. Comparison with publicly available 
datasets, however, suggested that prostate CAFs may be alternatively characterized by 
IL6 and TGFβ-related signatures, indicating that either signal, depending on the context, 
may concur to fibroblast activation. Our analyses also highlighted novel pathways 
potentially relevant for induction of a reactive stroma. In addition, we revealed a role 
for muscle-specific miR-133b as a soluble factor secreted by activated fibroblasts to 
support paracrine activation of non-activated fibroblasts or promote tumor progression.
Overall, we provided insights into the molecular mechanisms driving fibroblast 
activation in PCa, thus contributing to identify novel hits for the development of therapeutic 
strategies targeting the crucial interplay between tumor cells and their microenvironment.
INTRODUCTION
Tumor microenvironment is a dynamic and 
heterogeneous system of untransformed cells, growth factors, 
cytokines and pro-angiogenic molecules that coevolves with 
cancer progression [1]. The most representative nonmalignant 
stromal cells in the cancer microenvironment are fibroblasts, 
mesenchymal cells of the connective tissue that are embedded 
within the extra-cellular matrix (ECM). In normal epithelia, 
fibroblasts are responsible for tissue architecture, function 
and homeostasis by maintaining epithelial-mesenchymal cell 
interactions [2]. In the cancer context, in contrast, fibroblasts 
may favor the development of age-related proliferative 
disorders by altering the tissue microenvironment, enhancing 
several extrinsic tumor-promoting processes and becoming 
the so-called cancer-associated fibroblasts (CAFs) [3].
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Little is known about the molecular mechanisms that 
lead to activation of CAFs from tissue-resident fibroblasts, 
circulating marrow-derived fibroblast progenitors or 
mesenchymal stem cells [2]. Phenotypically, CAFs resemble 
myofibroblasts, as they are characterized by the expression 
of α–smooth muscle actin (α-SMA), contractile stress fibers, 
up-regulated synthesis of ECM and ECM remodeling 
proteases, resulting in deposition of a reactive stroma. 
For this reason TGFβ, which is known to be involved in 
myofibroblast differentiation during wound repair [4], has 
been long considered the most prominent cancer cell-derived 
factor able to transform resident fibroblasts into CAFs.
A reactive stroma exhibiting ECM alterations typical 
of wound healing has been observed in prostate cancer (PCa) 
and even in precancerous lesions (e.g. PIN), suggesting a role 
for TGFβ [5]. Accordingly, in vitro studies have shown that 
tumor-derived TGFβ is able to induce activation of human 
prostate stroma through heavy deregulation of key signalling 
pathways crucially involved in maintaining tumor-promoting 
features, including FGF2, CTGF, SDF1, WNT3A and IGF 
axes [6, 7]. However, mounting evidence demonstrates that 
CAFs may be a heterogeneous cell population within a single 
tumor or adopt different phenotypes depending on the tumor 
type [8]. For example, Planche [9] showed that invasive 
breast and prostate reactive stromas display incomplete 
overlap of global gene expression profiles. Moreover, 
they found a correlation between patient clinical outcome 
and breast or prostate deregulated stromal genes, but not 
a common survival predictive gene signature of activated 
stroma for both tumor types [9].
Different CAF transcriptomic phenotypes may be 
reflective of activation by different tumor-derived stimuli. 
In this regard, we have recently showed, in the PCa setting, 
that tumor-derived interleukin-6 (IL6), via the secretion of 
soluble factors including metalloproteases, may itself activate 
normal fibroblasts and subsequently (i) induce epithelial-
mesenchymal transition (EMT) in PCa cells, thus increasing 
their invasive capability, (ii) favor the expression of stemness 
markers, and (iii) support PCa growth and metastasis in vivo, 
as also observed for patient-derived CAFs [10]. Altogether, 
such preliminary evidence would suggest a role for IL6 in 
activating human prostate fibroblasts (HPFs) to CAFs.
In the present study, patient-derived CAFs and 
HPFs activated in vitro with either TGFβ or IL6 were 
comparatively analyzed for gene and microRNA (miRNA) 
expression profiles, with the aim to define transcriptional 
pathways responsible for fibroblast activation and establish 
whether different subpopulations of CAFs may exist in PCa.
RESULTS
Comparative gene expression profiling reveals major 
transcriptome similarities between IL6-activated 
fibroblasts and patient-derived prostate CAFs
To analyze the transcriptomic changes associated with 
fibroblast activation and acquisition of tumor-promoting 
features, gene expression profiles were comparatively 
evaluated in fibroblasts derived either from the tumor 
(Cancer Associated Fibroblasts, CAFs) or from the adjacent 
non-neoplastic areas (Human Prostate Fibroblasts, HPFs) 
of three radical prostatectomies (Gleason score 4+5, pT3a, 
N0). HPFs activated in vitro with TGFβ or IL6 have been 
included in the analysis to understand whether either 
signals may be able to induce part of the transcriptomic 
changes occurring in patient-derived CAFs. Unsupervised 
hierarchical clustering of the specimens revealed that 
TGFβ-stimulated HPFs were characterized by a markedly 
different gene expression profile compared to the other 
fibroblast types (Figure 1). On the contrary, IL6-stimulated 
HPFs showed transcriptional profiles highly similar to 
CAFs, driving a “per patient” clustering (Figure 1).
To obtain further information about the molecular 
events occurring in activated fibroblasts, each type of 
activated fibroblasts was compared to HPFs using a gene 
set enrichment analysis (GSEA). Initially, we attempted 
to characterize the transcriptomic phenotype of patient-
derived CAFs (Figure 2A). We found positive enrichment 
of terms related to the actin cytoskeleton remodeling and 
muscle contractility, thus supporting the well-known 
similarity between CAFs and myofibroblasts. Intersection 
of leading edge genes from the enriched gene sets of 
the cytoskeleton-muscle contraction network revealed 
major up-regulation of myosin light chain subunits 
and regulatory proteins, as well as regulators of actin 
cytoskeleton assembly (Supplementary Table S1). In 
addition, and in trend with our previous observations 
[11], CAFs also exhibited enrichment of genes involved 
in carbohydrate metabolism (Figure 2A). Interestingly, 
among positively enriched gene sets there were also 
the “voltage gated cation channel activity” gene set 
(Supplementary Figure S1), containing genes that code for 
calcium and potassium channels probably involved in the 
acquisition of a contractile phenotype, and the “interferon-
alpha-beta signalling” gene set, which contains genes that 
are likely modulated upon cytokine stimulation (including 
IL6, i.e. Interferon-β) in vivo (Figure 2A).
Among down-regulated genes, enrichment was 
found for terms related to growth hormone/FGF signaling 
and, surprisingly, TGFβ signaling (including genes coding 
for SMAD and BMP proteins) (Figure 2A, Supplementary 
Figure S1). In addition, a “pregnancy–related” gene 
set was found, mainly consisting of PSG (pregnancy 
specific beta-1-glycoprotein) glycoproteins, the role of 
which in cancer stroma is still to be explored (Figure 2A, 
Supplementary Figure S1).
GSEA analysis was then extended to in vitro 
activated fibroblasts for comparative purposes. The 
positively and negatively enriched terms (P-value < 0.05) 
in at least two comparisons are shown in (Figure 2B). Only 
few gene sets were commonly enriched in all comparisons: 
glycolysis/gluconeogenesis and cardiomyopathy–the latter 
including genes involved in muscle contraction–among 
positively enriched gene sets, and growth hormone/
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FGF signaling among negatively enriched terms (Figure 
2B, Supplementary Figure S2). In contrast, the gene set 
“interferon-alpha-beta signalling” was coherently enriched 
in genes up-regulated in either CAFs or IL6-activated 
fibroblasts whereas showed an opposite trend in TGFβ-
HPFs (Figure 3). Also terms related to extracellular region 
part showed differential enrichment in CAFs or IL6-HPFs 
compared to TGFβ-HPFs (Figure 3), corroborating the 
hypothesis that, despite phenotypic similarities, gene 
expression of myofibroblasts diverges from that of patient-
derived CAFs. Major overlap was indeed observed in gene 
sets enriched in IL6-stimulated HPFs and CAFs compared 
with HPFs, including pathways related to contractile 
fibers, muscle contraction, voltage gated channels 
(positive enrichment), reproductive process and pregnancy 
(negative enrichment) (Figure 2B).
Interesting observations emerged by looking at 
single gene differential expression as well. For example, 
all activated fibroblasts showed up-modulation of ACTA2 
(i.e., α-SMA), which is consistent with their activated state 
(Supplementary Table S2). Accordingly, IL6-stimulated 
HPFs exhibited a more elongated cell morphology when 
compared to HPFs and were characterized by increased 
expression of α-SMA (green), which was organized 
into contractile fibers (Figure 4A), similarly to TGFβ-
HPFs. Enhanced staining for collagen 1A1 (Figure 
4A) and increased fibroblast activation protein (FAP) 
levels (Figure 4B) were also observed, as assessed by 
immunofluorescence and immunoblotting, respectively. It 
is worth mentioning, however, that the most evident up-
regulation of α-SMA was observed upon TGFβ stimulation 
(Figure 4B). TGFβ-stimulated fibroblasts were actually 
characterized by an enlarged, flatted morphology with 
dense contractile fibers, whereas IL6-HPFs maintained 
the fibroblast characteristic fusiform shape with extended 
cellular processes (Figure 4A). IL6-activated fibroblasts 
also showed increased levels of p16 and p21 cell cycle 
inhibitors, which may account for a senescent-like 
phenotype (Figure 4B). Consistent with this, increased 
trimethylation of H3 histone on lysine 9 (3meH3K9) 
and number of γ-H2AX foci (Figure 4C) were detected 
in HPFs upon IL6 stimulation, confirming our previous 
evidence showing that activated fibroblasts share features 
of senescent fibroblasts and viceversa [12].
Differential analysis also highlighted that whilst 
TGFβ-HPFs were characterized by higher TGFβ1/2 
expression levels than normal fibroblasts, CAFs and 
IL6-stimulated HPFs shared increased expression of the 
alternative ligand TGFβ3 (Supplementary Table S2). 
Notably, TGFB3 mRNA was markedly down-regulated in 
TGFβ-HPFs, thus suggesting a differential involvement of 
TGFβ family members and downstream signalling in the 
different types of activated fibroblasts. Involvement of 
TGFβ3 pathway in prostatic CAFs has been already reported 
by van der Heul-Nieuwenhuijsen [13], who also showed 
opposite regulatory effects of TGFB3 compared to FOXF2 
Figure 1: Unsupervised analysis of prostate fibroblast gene expression profiles. Gene expression profiles of CAFs, adjacent 
normal fibroblasts (HPF) and either TGFβ- or IL6-activated fibroblasts were subjected to hierarchical clustering using Euclidean distance 
and average linkage. Resulting dendrogram was reported and patient ID was color-coded according to the legend.
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transcription factor [13]. Curiously, PSG genes, found to 
be down-regulated only in CAFs and IL6-stimulated HPFs 
(Supplementary Table S2), are regulated by FOXF2 [13]. 
Up-modulation of distinct sets of metalloproteases was also 
observed in IL6- vs TGFβ-stimulated fibroblasts, namely 
MMP11 in the former and MMP1-2-10-14-23A in the latter 
(Supplementary Table S2).
As next step, gene expression profiles emerging 
from our analyses have been challenged on publicly 
available gene expression profiles of prostate 
Figure 2: Gene set enrichment analysis. A. Graphical representation of positively (red) or negatively (blue) enriched gene sets in 
CAFs (n = 3) compared with HPFs (n = 3). Node size is proportional to the number of genes included in the gene set, whereas link thickness 
is proportional to the number of common genes. B. Heatmap summarizing significantly enriched gene sets in at least two of the evaluated 
comparisons (CAF vs HPF, IL6-HPF vs HPF, TGFβ-HPF vs HPF, n = 3 for each group).
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microdissected stroma [9] or CAFs [14]. Results showed 
that, in general, gene expression of tumor stroma was 
positively correlated with all signatures of activated 
fibroblasts (CAF, IL6 or TGFβ) (Figure 5). Specifically, 
though some tumor stroma samples were characterized 
by a clear TGFβ signature, others rather showed an IL6 
profile (Figure 5), thus validating our findings concerning 
a possible role of IL6 in activating prostate fibroblasts 
in vivo. These findings may suggest the possible co-
existence of TGFβ- and IL6-activated fibroblasts within 
prostate tumor stroma; further investigation will be 
carried out to understand when and where activation 
of resident fibroblasts by cancer cells is preferentially 
driven by TGFβ or IL6. Surprisingly, fibroblasts obtained 
from a benign prostatic hyperplasia (BPH) specimen in 
Zhao dataset (marked with an asterisk in Figure 5) were 
characterized by IL6 and CAF signatures, suggesting that 
gene expression characteristic of an activated stroma may 
be found even in lesions that still appear as non-malignant 
from a histological point of view.
Comparative miRNA expression profiling 
identifies miRNAs involved in fibroblast 
activation induced by different stimuli
MiRNA expression profiling was carried out on 
the same samples used for gene expression analyses. 
After quality control, CAF_1 sample, classified as outlier 
because highly divergent from all the other samples in an 
unsupervised analysis, was removed and the remaining 
samples were used to perform a paired class comparison 
between activated and normal HPFs, as previously 
described for gene expression analyses. The different 
sample size would have made a direct comparison between 
the number of differentially expressed miRNAs biased. 
As an alternative, the differentially expressed miRNAs 
(P-value < 0.05) in either IL-6 or TGFβ-stimulated 
fibroblasts vs HPFs were evaluated as a “miRNA set” 
on the miRNA list ranked according to t-statistic values 
obtained by comparing CAFs vs HPFs. Again we found 
that both up- and down-regulated miRNAs in IL6-
Figure 3: Selected gene set enrichment plots. Example of gene sets having divergent enrichment between CAF/IL6-HPFs and 
TGFβ-HPFs (vs HPF). The analysis was performed using GSEA that calculate an Enrichment Score (ES) by walking down the list of genes 
ranked according with the t-statistics value of the reported comparison, increasing a running-sum statistic when a gene is in the gene set and 
decreasing it when it is not (green line). A positive ES indicates gene set enrichment at the top of the ranked list (red part of the horizontal 
bar); a negative ES indicates gene set enrichment at the bottom of the ranked list (blue part of the horizontal bar). The middle portion of 
the plot shows where the members of the gene set appear in the ranked list of genes. The bottom portion of the plot shows the value of the 
ranking metric as you move down the list of ranked genes.
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Figure 4: IL6-induced phenoconversion of normal prostate fibroblasts into activated fibroblasts. A. Representative 
immunofluorescence images of primary normal prostate fibroblasts (HPFs) treated with IL6 or TGFβ, the latter used as positive control for 
myofibroblast-like differentiation (Magnification: 40×). α-SMA and Collagen1A1 were stained in green and red respectively. IL6-activated 
fibroblasts showed increased staining for both markers, suggesting an activated phenotype, though maintaining a characteristic spindle-like 
shape with extended cellular processes compared to TGFβ-HPFs. B. Representative immunoblotting for activation and senescence markers. 
Fibroblast activation of both IL6- and TGFβ-stimulated HPFs was confirmed by increased α-SMA and FAP protein amounts. IL6-HPFs also 
showed enhanced expression of senescence-related p21 and p16 proteins. C. Representative images of 3meH3K9 (magnification: 40×) and 
γH2AX (magnification: 60×) staining confirmed senescent-like phenotype of IL6-activated fibroblasts.
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HPFs showed the same trend in CAFs (Figure 6A, 6B). 
Conversely, miRNAs up-regulated in TGFβ-HPFs were 
not significantly enriched (FDR = 0.123) in CAFs (Figure 
6C), whereas miRNAs repressed in TGFβ–HPFs were also 
down-regulated in CAFs (Figure 6D). Notably, miRNAs 
down-regulated in either IL6- or TGFβ-HPFs and 
commonly repressed in CAFs were specific for each of 
the two stimuli. For example, CAFs and IL6-HPFs shared 
the down-modulation of miR-762 (Figure 6B), which is 
predicted to target α-SMA in its 3′UTR (predictions made 
by RNA22 tool, [15]). MiRNAs commonly repressed 
in CAFs and TGFβ-HPFs were instead miR-26a, miR-
221/222, miR-490-5p/3p and others (Figure 6D).
MiRNAs up-regulated in all activated fibroblasts 
were miR-210, miR-143 and miR-590-5p (Figure 6A, 
6C), a result that was validated by qRT-PCR (Figure 6E). 
In this regard, we already showed that miR-210 is indeed 
able to activate HPFs, when ectopically overexpressed 
[12]. Analysis of genes correlated with each of these 
miRNAs revealed major commonalities between miR-210 
and miR-590-5p, thus suggesting that these two miRNAs 
may govern the same pathways, such as the regulation 
Figure 5: Correlation between activated fibroblast signatures and prostate stroma expression profiles. Three distinct centroids 
were derived from differentially expressed genes between CAF vs HPF, IL6-HPF vs HPF or TGFβ-HPF vs HPF (n = 3 for each group), and 
correlated with expression profiles from microdissected tumor/normal stroma (Planche dataset, upper panel) or tumor/normal fibroblasts (Zhao 
dataset, lower panel). Results were summarized as a heatmap, positive correlations are in red and negative correlations in blue.
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Figure 6: miRNA expression analysis. A–D. Significantly up- (A) and down-regulated (B) miRNAs in IL6-HPFs (n = 3) or up- 
(C) and down-regulated (D) in TGFβ-HPFs (n = 3) compared with HPFs (n = 3) were used as miRNA sets tested for enrichment in the 
comparison between CAF and HPF miRNA expression profiles. Coherent or divergent expression of miRNAs within miRNA sets with 
respect to CAF/HPF trend is reported. MiRNAs coherently modulated in all types of activated fibroblasts are highlighted in red. In green 
are miRNAs belonging to miR-17~92 cluster, in bold muscle-specific miRNAs, both groups being coherently modulated in IL6-activated 
fibroblasts and patient-derived CAFs. E. qRT-PCR validation of miRNAs found to be up-regulated in patient-derived CAFs, IL6-HPFs and 
TGFβ-HPFs. Date were reported as -∆∆Ct with respect to serum-starved HPFs of three independent experiments. **P < 0.01.
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of translation (as evidenced by various gene sets among 
the positively correlated genes) or insulin receptor 
recycling (among negatively correlated genes) (Figure 
7A). Curiously, a negative correlation was found with the 
term “female pregnancy”, which includes genes that we 
actually observed to be down-regulated in CAFs. Genes 
correlated with miR-143 were instead mostly related to 
ECM organization (positive correlation) or oxidative 
phosphorylation (negative correlation), both aspects being 
consistent with the phenotype of all activated fibroblasts 
(Figure 7A).
IL6-activated fibroblasts additionally shared with 
patient-derived CAFs up-regulation of miR-17~92 family 
members, as well as that of muscle- and heart-specific 
miR-1 and miR-133b (Figure 6A). When tested by qRT-
PCR, a marked up-regulation of miR-1 and miR-133b 
was actually found in IL6-HPFs and CAFs, but even 
to a lesser extent, up-modulation of the miRNAs was 
also detected in TGFβ-HPFs (Figure 6E). These two 
miRNAs are well known as essential rulers of muscle cell 
function and cardiomyocyte differentiation [16], which is 
consistent with the enrichment of terms related to muscle 
contractility and heart morphogenesis found in CAFs 
(Figure 2A).
Prototypic IL6-related miR-133b is released by 
CAFs and induces per se fibroblast activation
MiR-133b was chosen as a prototype of miRNAs 
up-regulated in IL6-stimulated fibroblasts, as it was also 
the top ranking in CAF vs HPF comparison (Figure 6A). 
Analysis of genes correlated with miR-133b revealed 
negative correlation with mitochondrion-related genes, 
including those involved in oxidative phosphorylation 
and respiratory chain (Figure 7B), with this finding being 
in trend with the glycolytic metabolism of CAFs. Among 
positively correlated genes, enrichment for terms related 
to cytokines and interferon signalling was found (Figure 
7B). This may be related both to miR-133b up-regulation 
found in CAFs as a consequence of IL6 (and possibly 
other cytokines) stimulation, as well as to a role for the 
miRNA in regulating the secretion of soluble factors. In 
this regard, it was striking to find that the levels of miR-
133b were also increased in the conditioned media of 
primary normal fibroblasts activated in vitro with IL6 or 
TGFβ as well as those of patient-derived CAFs compared 
to the media obtained from non-activated HPFs, with a 
major release found upon IL6 stimulation (Figure 8A). 
Possibly, miR-133b may itself represent a soluble factor 
secreted by activated fibroblasts to support paracrine 
activation of non-activated fibroblasts or promote tumor 
progression. When exosomes were isolated from the 
fibroblast media, again we found increased abundance 
of miR-133b in exosomes from CAFs compared to those 
from HPFs (Figure 8B). However, comparison of miR-
133b threshold cycles between whole media and exosomal 
fraction preliminarily suggested that miR-133b may be 
only in part released through exosomes (Figure 8B).
To investigate miR-133b ability to induce fibroblast 
activation, primary normal fibroblasts were directly 
transfected with miR-133b. Overexpression of the 
miRNA (as assessed by qRT-PCR, Figure 8C, left bar) 
resulted in marked morphological changes, with increase 
in the number of elongated cells reminiscent of IL6-
stimulated fibroblasts (Figure 8D). Accordingly, qRT-
PCR revealed up-modulation of a number of fibroblast 
activation markers, such as ACTA2, FAP, S100A4 and 
COL4A2 (Figure 8E). In addition, immunofluorescence 
analysis confirmed changes in morphology together 
with increased staining for α-SMA and FAP (Figure 8D). 
Overexpression of miR-133b resulted in an enhanced 
secretion of the miRNA, as assessed by qRT-PCR on 
the media of transfected cells (Figure 8C, middle bar), 
thus confirming miR-133b as one of the mediators of the 
secretory phenotype of activated fibroblasts. Strikingly, 
endogenous miR-133b expression levels also increased 
in PC3 cells stimulated with the conditioned medium of 
miR-133b-activated fibroblasts (Figure 8C, right bar). 
Even to a lesser extent, miR-133b levels also increased 
in PC3 cells stimulated with media from IL6- or TGFβ-
activated fibroblasts, or CAFs (Figure 8F). As the levels 
of miR-133b primary transcript were even down-regulated 
in stimulated PC3 cells (Figure 8F), it is conceivable that 
tumor cells may uptake mature miR-133b directly from 
the medium of activated fibroblasts and, as a consequence, 
repress the endogenous transcription of the miRNA.
A different scenario emerged for miR-210, up-
regulated in all types of activated fibroblasts (Figure 6A, 
6C) and able per se to activate HPFs when ectopically 
overexpressed [12]. In fact, the expression levels of 
both the mature and the primary transcript of miR-210 
increased in PC3 cells upon stimulation with activated 
fibroblasts, thus suggesting a direct transcriptional 
activation rather than a transfer from the fibroblast media, 
as instead observed for miR-133b (Figure 8F). In this 
regard, we have previously shown that CAFs elicit in 
PCa cells a pro-oxidant response, which culminates in 
the overexpression of hypoxia-inducible factor-1 (HIF-
1), which in turn regulates transcription of its targets, 
including miR-210 [10, 17, 18].
To confirm the capability of PC3 cells to directly 
internalize miRNAs present in fibroblast media (i.e. 
miR-133b), we performed a couple of experiments 
where a spike-in miRNA was added to the medium prior 
stimulation of PC3 cells. In the first setting, a Cy3-labeled 
miRNA mimic was used and miRNA internalization was 
assessed by fuorescence microscopy. In the latter, we 
used a non human miRNA (ath-miR-159a), and miRNA 
uptake by tumor cells was evaluated by qRT-PCR for ath-
miR-159a. In both settings, after a 24 h-stimulation, PC3 
cells were washed thrice to remove any residual miRNA 
remaining on cell surface. Results showed that PC3 cells 
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Figure 7: Integration of gene and miRNA expression data. A. Gene expression data were correlated with expression levels of 
miR-590-5p, miR-210 or miR-143 respectively. Genes were then ranked according with the correlation value and subjected to gene set 
enrichment analysis. Enriched gene sets are summarized as a heatmap. Red indicates positive enrichment and blue negative enrichment; 
darker colors indicate higher statistical significance according to the legend. B. The same analysis in (A) was repeated for miR-133b and 
here represented as a graph. Node size is proportional to the number of genes included in the gene set, whereas link thickness is proportional 
to the number of common genes. Positive enrichment is in red and negative enrichment in blue.
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can readily internalize the miRNA present in the medium, 
as evidenced by fuorescent signal within the cytoplasm 
of cells stimulated with labeled miRNA (Figure 9A). In 
addition, PCR signal for non human ath-miR-159a became 
detectable in cells grown in the presence of synthetic ath-
miR-159a (Figure 9B), suggesting direct uptake from the 
medium. To ultimately confirm that miR-133b expression 
levels in PC3 cells stimulated by CAFs reflect the amount 
of miR-133b present in the fibroblast media, we attempted 
to modulate miR-133b expression in such media and 
then analyzed miRNA levels in stimulated tumor cells. 
To this purpose, we silenced DROSHA, one of the major 
Figure 8: miR-133b induces fibroblast activation and acts as soluble factor for paracrine stimulation of fibroblast and 
tumor cells. A. miR-133b expression levels were evaluated in conditioned medium (CM) from CAFs, IL6- or TGFβ-activated fibroblasts 
by qRT-PCR. miR-133b release in CM increased upon stimulation of HPFs with IL6 and, to a lesser extent, with TGFβ. Enhanced secretion 
of miR-133b was also found in CAFs. Data were analyzed using spike-in non-human synthetic miRNA as normalization control and 
were reported as −∆∆Ct with respect to CM from serum-starved HPFs of three independent experiments. B. miR-133b expression levels 
were evaluated in CM and extracellular exosomes from CAFs and HPFs by qRT-PCR. CAFs showed enhanced release of both total and 
exosome-associated miR-133b compared to HPFs. However, starting from equal RNA amounts, Cts were higher in exosomes (hence miR-
133b expression lower) with respect to total media, suggesting that miR-133b may be secreted in forms other than exosomes. C. qRT-PCR 
measurement of endogenous miR-133b levels in HPFs transfected with miR-133b mimics (vs cells transfected with miR-Neg), of miR-133b 
in the media of HPFs transfected with miR-133b mimics (vs media form cells transfected with miR-Neg), and of endogenous miR-133b in 
PC3 cells stimulated with CM from miR-133b-transfected cells (vs cells stimulated with CM from miR-Neg-transfected HPFs). Data were 
reported as –∆∆Ct respect to specific control of three independent experiments. D. Representative bright field and immunofluorescence 
(α-SMA and FAP staining) images of HPFs transfected with miR-133b mimics or miR-Neg (Magnification: 10×). Ectopic expression of 
miR-133b induced morphological changes and increase of activation markers reminiscent to those observed in IL6-activated fibroblasts. 
E. qRT-PCR assessment of ACTA2, FAP, S100A4 and COL4A2 to confirm fibroblast activation upon miR-133b overexpression in HPFs. 
qRT-PCR data were reported as −∆∆Ct respect to miR-Neg-transfected HPFs of three independent experiments. (Continued)
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components of miRNA processing machinery, in CAFs 
to reduce miRNA production. We tested two different 
siRNA molecules and found that siDROSHA-1 was 
more efficient in repressing DROSHA mRNA expression 
(Supplementary Figure S3). Accordingly, miR-133b 
endogenous levels decreased in CAFs upon DROSHA 
silencing by siDROSHA-1 (Figure 9C), lowering to levels 
found in HPFs (Figure 9C). Coherently, miR-133b levels 
decreased in the media from siDROSHA-1-transfected 
CAFs (Figure 9D), which were then used to stimulate PC3 
cells. Again, we found that endogenous miR-133b levels 
in PC3 cells increased upon stimulation with CM from 
siCTR-transfected CAFs compared to CM from HPFs 
(Figure 9E). However, DROSHA silencing and consequent 
reduced secretion of miR-133b by siDROSHA-1-
transfected CAFs resulted in less efficient uptake of miR-
133b by PC3 cells (Figure 9E).
Overall these experiments showed that PC3 cells 
directly internalize miR-133b from fibroblast media and 
that endogenous miRNA levels in tumor cells depend on 
the amount of miR-133b released by fibroblasts.
DISCUSSION
It is widely accepted that solid tumors are 
heterogeneous and complex systems consisting of neoplastic 
cells and untransformed stroma components. Such reactive-
stroma is a mixture of immune cells, endothelial cells 
and CAFs exhibiting activated phenotypes. CAFs are the 
predominant cell population in PCa microenvironment and 
are characterized by a phenotype reminiscent to that of 
fibroblasts involved in wound repair events [5]. Reciprocal 
interaction between cancer cells and CAFs influences each 
step of tumor development, growth and metastasis, mainly 
through the release of soluble growth factors [19]. In the 
context of PCa, we have previously shown that CAFs, 
through secretion of MMPs, elicit EMT and achievement of 
stem cell traits in cancer cells, as well as enhancement of 
tumor growth and development of spontaneous metastases 
[10]. We also reported that CAFs induce a Rac1b/ 
cycloxygenase-2-mediated release of reactive oxygen 
species in carcinoma cells, which activates nuclear factor-
κB and HIF-1 [17], and ultimately results in repression of 
miR-205 transcription. Inhibition of miR-205 function 
relieves a brake on its target genes, including E-cadherin 
transcriptional repressors, thus leading to establishment of 
EMT and enhancement of metastasis [18]. The other way 
around, tumor cells per se contribute to the formation of a 
reactive stroma. In this regard, we showed that PCa cells can 
activate normal fibroblasts to a phenotype reminiscent to 
that of patient-derived CAFs through the secretion of soluble 
factors, including IL6. In fact, stimulation of HPFs with 
the medium of castration-resistant PCa cells was sufficient 
to increase α-SMA and FAP expression and to promote the 
acquisition of tumor-promoting properties, a phenotype 
abrogated by the administration of an anti-IL6 antibody [10].
In the present study, we comparatively analyzed 
gene expression profiles of CAFs and HPFs obtained from 
radical prostatectomies to contribute to the understanding 
of the biology and signaling mechanisms involved in 
reactive stroma formation. Previous studies suggest 
that, compared to normal fibroblasts, CAFs found in 
tumors are characterized by enhanced collagen synthesis, 
secretion of growth factors and ECM modulators, and 
the activation of unique expression programs [20, 21]. 
Consistently, we found that CAFs are phenotypically 
Figure 8: (Continued) miR-133b induces fibroblast activation and acts as soluble factor for paracrine stimulation of 
fibroblast and tumor cells. F. pri-miR-133b, miR-133b, pri-miR-210 and miR-210 expression levels were assessed in PC3 cells upon 
stimulation with CM from HPF-IL6, HPF-TGFβ or from CAFs by qRT-PCR. Results showed direct uptake of miR-133b in PC3 cells from 
fibroblast media, as shown by paradoxical down-regulation of endogenous pri-miR-133. In contrast, fibroblast stimulation increased miR-
210 expression in PC3 cells by enhancing transcription of pri-miR-210, suggesting a different mechanism. Data were reported as −∆∆Ct 
with respect to PC3 cells stimulated with CM from HPFs. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Figure 9: PC3 cells directly internalize miR-133b from fibroblast media. A. Merged bright field and fluorescence images 
of PC3 cells grown in a medium supplied with Cy3-labeled spike-in miRNA (Cy3™ Dye-Labeled Pre-miR Negative Control #1, Life 
Technologies) or miR-Neg as a control (Magnification: 20×, insert 40×). B. qRT-PCR showing ath-miR-159a expression levels in PC3 cells 
were grown in a medium supplied with ath-miR-159a spike-in miRNA or miR-Neg as a control. Data are presented as ∆Ct compared to 
RNU48. Notably, signal for ath-miR-159a in miR-Neg sample was undetermined and Ct set to 40. C. Expression levels of endogenous miR-
133b in CAFs transfected with siCTR or siDROSHA-1. Data are presented as relative quantity vs HPFs. D. Expression levels of miR-133b 
in the media from CAFs transfected with siCTR or siDROSHA-1. Data are presented as relative quantity vs CM from HPFs. E. Expression 
levels of miR-133b in PC3 cells stimulated with the media from CAFs transfected with siCTR or siDROSHA-1. Data are presented as 
relative quantity vs PC3 cells stimulated with CM from HPFs. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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similar to myofibroblasts, with elevated expression 
levels of α-SMA and positive enrichment of genes that 
regulate actin cytoskeleton remodeling and muscle 
contractility. Moreover, activated fibroblasts showed 
positive enrichment for gene sets related to glycolysis/
gluconeogenesis pathway, in accord to our previous 
evidence that CAFs undergo a metabolic reprogramming 
from a respiratory to a glycolytic metabolism to support 
cancer progression [11]. CAFs also exhibited positive 
enrichment of gene sets related to “voltage gated cation 
channel activity”, as already observed in microdissected 
reactive stroma of grade 3 PCa [22]. Among down-
regulated gene sets, a “pregnancy-related” signature, 
mainly composed of PGS glycoproteins, was also 
found. However, the role of either signaling pathway in 
supporting the activation or function of PCa stroma is still 
to be explored.
Very scanty information is currently available on 
which is the cell population committed to generate CAFs. 
Lineage-tracing experiments showed that CAFs might 
evolve from tissue-resident mesenchymal stem cells or, by 
endothelial-to-mesenchymal transition, from endothelial 
cells, from vimentin-positive periacinar cells or from 
vessel-associated pericytes [21, 23, 7]. In addition to 
these local sources, circulating bone marrow-derived cells 
known as fibrocytes can be recruited and differentiated 
into myofibroblasts to support cancer progression. A 
further possible origin of CAFs is represented by smooth 
muscle cells. Normal prostate stroma is enriched of this 
particular cell population, which, during PCa progression, 
is actually replaced by CAFs [21, 23]. Moreover, several 
pieces of evidence suggest that CAFs might also derive 
from fibroblasts resident in the tissue affected by tumor, 
through direct activation by cancer-derived stimuli [7, 24].
Several boosts, such as cytokines, growth factors, 
TGFβ and HGF have been shown to regulate reactive 
stroma formation, by affecting directly or indirectly 
stroma cells [25]. Among these, TGFβ is the most 
important and well-studied candidate in maintaining the 
features of tumor-associated stroma, due to its pivotal 
role in wound repair and fibroproliferative diseases [4]. 
In vitro studies reported that TGFβ is able to induce 
normal prostate fibroblasts to acquire a myofibroblast-like 
reactive phenotype with overexpression of α-SMA protein, 
components of ECM and enhanced synthesis of collagen 
type 1– all features well documented in CAFs derived 
from patients [26, 27]. Paradoxically, however, ablation 
of TGFβ receptor 2 (TGFBR2) in prostatic fibroblasts 
resulted in spontaneous neoplasia, illustrating a tumor-
suppressive function of TGFβ signaling in early tumor 
development [28]. It can be hypothesized that, in the PCa 
context, TGFβ may be more relevant for maintaining 
CAF phenotype rather that providing stroma with 
tumor-initiating features. Accordingly, in vivo evidence 
suggests that TGFβ signaling activation in stroma cells 
has little impact on tumor initiation phase but is critical 
for all subsequent steps of tumor progression, where 
maintenance of wound healing-like niche may support 
tumor aggressiveness [29]. In general, accumulating 
evidence demonstrates that CAFs may be a heterogeneous 
cell population within a single tumor or adopt different 
phenotypes depending on the tumor type, suggesting both 
inter and intra-tumor stromal heterogeneity [8].
To better understand the signaling mechanisms 
involved in the formation of PCa-associated stroma and 
which tumor derived-stimuli are able to induce the reactive 
phenotype seen in vivo, we extended gene expression 
analysis on fibroblasts activated in vitro with TGFβ or IL6. 
We found that only few gene sets were coherently enriched 
in both types of activated fibroblasts and superimposable 
on those found in patient-derived CAFs. In contrast, the 
“interferon-alpha and beta signaling” and genes related to 
ECM regulation were positively enriched in both CAFs 
and IL6-activated fibroblasts but showed an opposite trend 
in TGFβ-HPFs. Globally, in our hands, a major overlap 
was found between transcriptomes of IL6-activated HPFs 
and CAFs compared to TGFβ-HPFs, though both in vitro 
activated fibroblasts showed phenotypic similarities 
with CAFs. The comparison with publicly available 
gene expression profiles revealed that, in general, all the 
three signatures of activated fibroblasts from our study 
positively correlated with those of PCa microdissected 
stroma or CAFs, and negatively correlated with normal 
counterparts. This finding supports the robustness of 
our data and again confirms the existence of IL6-driven 
activation patterns in PCa reactive stroma. However, 
these data also account for the existence of more classical 
TGFβ-activated myofibroblasts in PCa. It is likely that 
depending on tumor stage, patient age, cancer etiology 
(e.g. history of inflammatory diseases, such as prostatitis) 
or even tumor genetic background, different stimuli 
may be predominant in inducing activation of a reactive 
stroma. In this regard, it is worth mentioning that, for 
example, IL6-activated fibroblasts showed evidence of a 
senescent-like phenotype (induction of p16, p21, γ-H2AX 
foci and 3meH3K9), which may account for an age-
related activation process. Banerjee [30] already reported 
that tumor-derived IL6 is able to mediate an epigenetic 
silencing of DNA damage repair and reactive oxygen-
metabolism genes in prostate fibroblasts, ultimately 
resulting in DNA-damage associated secretory phenotype, 
characterized by H3 lysine 9 trimethylation and TGFBR2 
down-regulation. Notably, reduced TGFBR2 expression 
levels were also found in our IL6-activated fibroblasts and 
CAFs (not shown). In contrast, TGFβ-dependent activation 
may be prevalent in conditions that mimic wound healing, 
such as chronic inflammation.
Gene expression profiling studies of CAFs derived 
from large cohorts of PCa patients covering all possible 
sources of stromal heterogeneity are hence warranted 
to understand the prevalence of IL6- rather than TGFβ-
driven CAFs in prostate reactive stroma. In addition, it 
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must be noted that, at present, molecular markers of 
stroma subpopulations are still poorly defined. Activated 
fibroblasts are usually identified by their characteristic 
fusiform-shape, dense cytoskeletal fibres and increased 
expression of various mesenchymal proteins, such as 
vimentin, α-SMA and FSP1. However, other markers -not 
expressed in all fibroblasts- still need to be characterized 
to identify the multiple populations of fibroblasts and more 
properly define the tumor-derived stimuli able to trigger 
activation of specific reactive stroma subtypes.
MiRNA expression profiling confirmed the evidence 
arisen from gene expression analyses, namely that 
modulations in the miRnome mediated by IL6 stimulation 
are the same found in patient-derived CAFs compared 
to their non-activated counterparts and that only minor 
overlap exists between these two types of fibroblasts 
and TGFβ-HPFs. Nevertheless, a small set of miRNAs, 
including miR-210, miR-143 and miR-590-5p, was found 
to be coherently up-modulated upon activation induced 
by either stimulus, suggesting that fundamental processes 
sustaining reactive stroma formation may be regulated 
by such miRNAs. In this regard, we already showed that 
miR-210 is indeed able to convert HPFs into CAF-like 
cells, promote EMT in PCa cells, support angiogenesis 
and recruit endothelial precursor cells and monocytes/
macrophages [12].
Among miRNAs more specifically (even not 
exclusively) modulated in IL6-activated stroma was miR-
133b. The miRNA belongs to the cluster miR-206/133b, 
which has been shown to be highly expressed, together 
with miR-1/133a cluster, in the musculatures of flies, 
mice and humans and has been largely characterized as 
involved in regulating muscle cell function [16]. miR-133 
is also the first most abundant miRNA in the heart, where 
it has been shown to regulate genes involved in cardiac 
contractility, hypertrophy and electric conductance [31]. 
When administered together with a combination of cardiac 
transcription factors, miR-1 and miR-133 have been 
shown to foster conversion of human adult fibroblasts into 
cardiomyocytes [32].
Here we showed that ectopic overexpression of 
miR-133b is able per se to promote fibroblast activation 
by inducing phenotypic changes similar to those found 
in prostate CAFs in vivo. An intriguing scenario is hence 
emerging concerning a possible similarity between 
prostate CAFs and myocardiocytes, both cell types 
characterized by enhanced contractility. If properly 
validated by additional experimental data, this finding may 
open new opportunities for the translation of drugs already 
used in the cardiovascular field into anticancer regimens, 
with the ultimate goal of interrupting the tumor-supportive 
spur provided by reactive stroma. Potentially, to interfere 
with myocardiocyte-like phenotype of prostate CAFs, 
we may envision using antiarrhythmic drugs, which all 
function by reducing myocardiocyte contractility, though 
through different mechanisms. Actually, antiarrhythmic 
drugs have been classified into 4 classes (Vaughan-
Williams classification) based on their mechanism of 
action. For translation into regimens aimed to impair with 
the functions of tumor reactive stroma, class I (sodium-
channel blockers, such as procainamide, mexiletine or 
flecainide), class III (potassium-channel blockers, such 
as amiodarone) or class IV (calcium-channel blockers, 
verapamil) drugs may be tested, based on our evidence 
that sodium, potassium and calcium voltage-gated channel 
are highly up-regulated in CAF vs HPFs (Supplementary 
Figure S1). By mining the literature we found that some 
of the aforementioned drugs have been used in anticancer 
schedules to potentiate efficacy of chemotherapy, as is 
the case of verapamil (a clinical trial described in [33]) or 
amiodarone (in vitro studies [34]) which inhibit the activity 
of the efflux pumps responsible of multidrug resistance, or 
as analgesics (mexiletine, flecainide) [35]. Procainamide 
has been also shown to act as nonnnucleoside inhibitor of 
DNA methyltransferases in human cancer cells [36].
Our findings further showed that miR-133b is also 
released into the media of activated fibroblasts and is 
possibly taken up by PCa cells, where it may contribute to 
establish a mesenchymal phenotype. This may represent 
an additional mechanism by which CAFs induce EMT 
in tumor cells, through the direct transfer of miRNAs 
typically expressed in cells of the mesenchymal lineage. 
Moreover, it is likely that released miR-133b may act as a 
paracrine stimulus able to expand the reactive phenotype 
to adjacent fibroblasts, thus contributing to extend the 
stromal niche able to support cancer progression.
miR-133b has been consistently found as down-
regulated in prostate carcinomas compared to normal 
tissues in different studies [37; reviewed also by Gandellini 
(38)]. In our hands however, expression of the miRNA 
seems to be prevalent in fibroblasts compared to epithelial 
cells, even if tumor cells up-regulate the miRNA when 
in contact with CAFs. As a consequence, it is possible 
that most of miR-133b expression found in normal tissue 
samples could come from cells of mesenchymal origin, 
and that down-regulation in tumor specimens found by 
different authors could mostly reflect a higher epithelial 
(tumor) vs stromal cell ratio in the sample rather than a 
direct down-modulation of the miRNA in tumor cells. 
Actually, no proof has been provided on miR-133b 
silencing in epithelial cells along tumorigenesis. In 
addition, miR-133b down-regulation seems to be common 
to different tumor types [39], a scenario reminding that of 
miR-143/145 (notably our data suggest that also miR-143 
is up-regulated in CAFs). Indeed, down-regulation of such 
miRNA cluster has been repeatedly reported in different 
epithelial tumor types (including PCa). However, based 
on available data on the literature, a possible role for miR-
143/145 as cell-autonomous epithelial tumor suppressors is 
still controversial [40]. Similarly, contrasting results have 
been obtained regarding the oncogenic or oncosuppressive 
role of miR-133b in PCa models [37, 41–43]. Such 
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discrepancies may rely on the fact that overexpression of 
miR-133b in PCa cells generates artificial findings, as the 
miRNA mainly acts as a master regulator of mesenchymal 
features in cells of mesenchymal origin (e.g. fibroblasts) 
or in tumor cells that undergo EMT.
Overall, we provided evidence on how an integrated 
gene and miRNA profiling may supply interesting hints on 
pathways relevant for fibroblast activation and maintenance 
of a reactive stroma, with important implications for the 
understanding of the mechanisms of cancer progression. In 
addition, the study allowed us to generate useful working 
hypotheses for the formulation of novel therapeutic agents 
based on the targeting of tumor stroma.
MATERIALS AND METHODS
Microarray experiments and data processing
Microarray experiments were run by the Functional 
Genomics Unit/Service from the Fondazione IRCCS 
Istituto Nazionale Tumori, Milan, Italy. Extracted 
RNA was processed for gene expression analysis using 
the Illumina HumanHT-12 v4 chips (47,324 probes) 
as previously described [44]; Briefly, 800 ng of total 
RNA were reverse transcribed, labeled with biotin and 
amplified overnight using the Illumina RNA TotalPrep 
Amplification kit according to manufacturer’s protocol. 
One μg of the biotinylated cRNA was mixed with the 
Hyb E1 hybridization buffer and then hybridized at 58°C 
overnight. Array chips were washed with manufacturer’s 
E1BC solution, stained with 1 μg/mL Cy3-streptavidine 
and scanned with the Illumina BeadArray Reader. Raw 
data were generated using the Illumina BeadStudio 3.8 
software and processed using the lumi package [45] 
of Bioconductor. After quality control, data were log2 
transformed and normalized using the Robust Spline 
Normalization algorithm. Probes with a detection of P > 
0.01 in all samples were filtered out and, for each gene, the 
probe with the highest detection rate or higher interquartile 
range was retained for downstream analyses.
For miRNA expression analysis, SurePrint G3 
Human miRNA 8x60K microarrays from Agilent 
Technologies (custom design based on miRBase 17.0) 
were used as previously described [46]. Two μg of 
RNA were labeled and processed according to the 
manufacturer’s recommended protocol. Samples were 
dephosphorylated with calf intestinal alkaline phosphatase, 
followed by denaturation in the presence of dimethyl 
sulfoxide. A dye, cyanine 3-pCp, was then coupled to 
the dephosphorylated single-stranded RNA by T4 RNA 
ligase. After hybridization for 20 h at 55°C, the arrays 
were washed in Agilent GE Wash Buffers, following the 
manufacturer’s instructions. All slides were immediately 
scanned at 2 mm resolution using an Agilent DNA 
microarray scanner. The resulting images were analyzed 
using Agilent’s Feature Extraction software v10.7.
One to 4 different probes can target each miRNA and 
each probe is spotted 10 to 40 times on the array. The total 
gene signal for each miRNA was obtained by summing the 
probe signals derived with the Agilent Feature Extraction 
software. Each probe was defined as detected if its value 
is greater than 3 times its standard error, and each miRNA 
was defined as detected if at least one of the probes was 
detected. Data were log2 transformed and normalized using 
the Robust Spline Normalization algorithm. Only human 
(“has”) miRNAs detected in at least two samples were 
selected for downstream analyses. Both gene and miRNA 
expression data were deposited to the Gene Expression 
Omnibus data repository (GSE68166) [47].
Unsupervised and supervised analyses
Hierarchical clustering using Euclidean distance and 
average linkage was applied for an unsupervised analysis of 
the data. Class comparison analyses were performed using 
a linear modeling approach and empirical Bayes methods 
as implemented in the limma Bioconductor package [48]. 
Gene set enrichment analysis was performed using GSEA 
v4.0 [49] on the gene list ranked according with the modified 
t-statistics from the class comparison analysis. A gene set 
collection including canonical pathways and signatures from 
the literature (C2), as well as gene ontology terms (C5) from 
the MSigDB database (http://www.broadinstitute.org/gsea/
msigdb) were tested for enrichment. The gene sets with P < 
0.01 were considered significantly enriched and represented as 
functional enrichment network using a Cytoscape plugin [50].
Centroid based signature evaluation in publicly 
available datasets
Differentially expressed genes [p-val < 0.01 for CAF 
or IL6-HPF vs HPF comparison; adj-p-val < 0.0001 for 
TGFβ-HPF vs HPF (in order to have a similar number of 
genes)] identified by class comparison analysis for each 
of our comparisons were used to define three different 
centroids representative of activated fibroblasts. The 
expression level of genes included in each centroid 
was calculated as the average expression in activated 
fibroblasts (CAF, IL6 and TGFβ). The three centroids 
were evaluated in two publicly available datasets of 
prostate microdissected stroma (GSE26910, [9]) and CAFs 
(GSE6250, [14]). Other potentially interesting datasets 
were excluded due to unsuitable sample size or failure of 
quality control. For both suitable datasets, the processed 
data downloaded from the Gene Expression Omnibus data 
repository [47] were used. Similarity between our centroids 
and tumor-stroma/CAFs expression profile for the same 
genes was evaluated and results plotted in a heatmap.
Experimental models
Human PCa cells (PC3) were purchased from 
the European Collection of Cell Cultures (ECACC) and 
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maintained at 37°C/5% CO2 in DMEM medium supplemented 
with 10% fetal bovine serum. Human prostate fibroblasts, 
HPFs and CAFs, were isolated from healthy and intratumoral 
regions, respectively, of the prostate of PCa-bearing patients 
(Gleason score 4+5). Tissue samples were obtained aseptically 
from patients undergoing radical prostatectomy, upon 
informed consent in accord with the Ethics Committee of 
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano. 
Tissues were digested overnight in DMEM supplemented with 
5% fetal bovine serum and 1× Collagenase-Hyaluronidase 
Solution (STEMCELLTM Technologies Inc.). Cell suspension 
was centrifuged at 1,500 g for 5 minutes. The resulting 
fibroblast-rich pellet was suspended and plated in DMEM 
containing 10% fetal bovine serum and 4 mM L-Glutamine. 
Expression of E-cadherin and cytokeratin was assessed to 
exclude epithelial contamination of either HPFs or CAFs. 
HPFs and CAFs were maintained in culture for 6 passages 
after tissue isolation and then used for the analysis.
Preparation of conditioned media
CM from HPFs, activated-HPFs, 133b-HPFs and 
CAFs were obtained from cells grown to sub-confluence, 
then serum starved for 48 h. CM were then harvested, 
clarified by centrifugation, and used freshly. Exosomes were 
isolated from 10 ml of culture media of either 48 h-serum 
starved HPFs or CAFs by ExoQuick-TCTM (System 
Biosciences, SBI), according to manufacturer’s instruction.
Fibroblast activation
HPFs were grown to sub-confluence and treated for 
48 h with 10 ng/ml rTGFβ1 or 50 ng/ml IL6. Fresh serum-
free medium was added for an additional 24 h before 
collection of CM.
Transfection
miR-133b mimic and negative control (miR-Neg) 
were purchased as mirVana® miRNA mimic molecules 
(Life Technologies, Carlsbad, CA, USA). Two siRNAs 
targeting DROSHA mRNA were designed: siDROSHA-1 
(5′-AACGAGUAGGCUUCGUGACUU-3′) and siDROS 
HA-2 (5′-AAGGACCAAGUAUUCAGCAAG-3′). A non- 
targeting siRNA (siCTR, 5′-GCAUACAAUGGAGUUGU 
UA-3′) was used as control. Cells seeded at the appropriate 
density were transfected for 4 h at 37°C with 20 nM 
miRNA mimic or siRNA using Lipofectamine-2000 (Life 
Technologies), according to the manufacturer’s instruction, 
and processed at different time intervals.
RNA extraction
Total RNA from cells was extracted using TRIzol® 
reagent (Life Technologies), according to the manufacturer’s 
instructions. miRNA from CM was isolated using miRNeasy 
Kit (Qiagen, Hilden, Germany). Briefly, before miRNA 
extraction, CM was collected and sequential centrifugation 
was performed. Clarified-CM was first centrifuged at 14,000 g 
for 10 minutes, and then centrifuged at 1,000 g for 5 minutes. 
350 μl of clarified and centrifuged CM was mixed with 1.6 
pmol of spike-in non-human synthetic miRNA (mirVana 
miRNA mimic ath-miR-159a), providing an internal 
reference for normalization of technical variations between 
samples. Then, RNA was extracted using miRNeasy Kit, 
according to the manufacturer’s instructions.
miRNA and gene expression analysis
Quantification of miR-1, miR-133b, miR-143, 
miR-590-5p, miR-210, pri-miR-133b and pri-miR-210 
expression levels was assessed by qRT-PCR using the 
following TaqMan® microRNA expression assays (Life 
Technologies): miR-1, 002222; miR-133b, 002447; miR-
143, 002249; miR-590–5p, 001984; miR-210, 000512; 
primary miR-133b, Hs03303651_pri; primary miR-210, 
Hs03302948_pri. mRNA expression was measured by qRT-
PCR using the following Taqman® gene expression assays: 
ACTA2, Hs00426835_g1; DROSHA, Hs00203008_m1; 
FAP, Hs00990806_m1; S100A4 Hs00243202_m1; COL4A2, 
Hs00266237_m1. Amplifications were run on the 7900HT 
Fast Real-Time PCR System. Data were analyzed by SDS 
2.2.2 software (Life Technologies) and reported as relative 
quantity with respect to a calibrator sample using the 2-∆∆Ct 
method. RNU48 (PN4427975) and GAPDH (PN4326317E) 
were used as normalizers for miRNAs and pri-miRNAs/
mRNA expression, respectively. Spike-in miRNA ats-miR-
159a (000338) was used as normalizer for miRNAs from CM.
Immunofluorescence analysis
Cells were seeded on μ-Slide 8 well chamber (IBIDI 
GmbH, München, Germany), fixed in 4% formaldehyde/PBS 
for 15 min and incubated in methanol/acetone or 70% cold 
ethanol for 15 min at room temperature. Cell were probed 
with anti alpha-SMA (A2547; Sigma-Aldrich, St. Louis, MO, 
USA), anti-FAP (sc-65398; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), anti-S100A4 (ab27957; Abcam, Cambridge, 
UK), anti-collagen I (ab34710; Abcam), anti- 3meH3K9 
(ab8898; Abcam) or anti-gamma H2A.X (ab11174; Abcam) 
primary antibodies for 1 h and Alexa fluor488-labeled or Alexa 
Fluor594-labeled (Life Technologies) secondary antibodies 
for 1 h at room temperature. Nuclei were counterstained with 
0.1 ug/ml of 4′, 6-diamindino-2-phenylindole (DAPI, Life 
Technologies). Images were acquired using a Nikon Eclipse 
E600 microscope by ACT-1 software (Nikon corporations, 
Tokyo, Japan) and processed by ImageJ.
Immunoblotting analysis
Cells were lysed for 30 min on ice in lysis buffer 
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 
1 mM phenylmethanesulphonyl-fluoride, 5 μg/ml aprotinin, 
20 μg/ml leupeptin). Lysates were clarified by centrifugation, 
and twenty μg of protein extracts were fractionated by SDS-
PAGE and transferred onto nitrocellulose using standard 
protocols. Equal protein loading was verified by Ponceau 
staining. Filters were blocked in PBS 1X Tween-20 with 5% 
of skim milk and incubated overnight with primary specific 
antibodies for α-SMA (A2547; Sigma-Aldrich), FAP (sc-
65398; Santa Cruz Biotechnology), p21 (ab7960; Abcam), 
Oncotarget18www.impactjournals.com/oncotarget
p16 (ab7962; Abcam) and Vinculin (V9131; Sigma-Aldrich). 
The filters were then incubated with the secondary peroxidase 
linked whole antibodies. Bound antibody was detected using 
the Novex ECL, HRP Chemiluminescent substrate Reagent 
Kit (Life Thecnologies).
Statistical analysis
Data are presented as mean values ± SD from at least 
three independent experiments. Statistical analysis of the data 
was performed by two-tailed Student’s t test. P-values < 0.05 
were considered statistically significant. Statistics applied to 
microarray analyses is described in the relative sections.
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